APA (7th ed.) Citation

Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., . . . Lo, H. (2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells (2073-4409), 13(24), 2087. https://doi.org/10.3390/cells13242087

Chicago Style (17th ed.) Citation

Manore, Sara, Chuling Zhuang, Mariana K. Najjar, Grace L. Wong, Shivani Bindal, Kounosuke Watabe, Jiayuh Lin, and Hui-Wen Lo. "Co-Inhibition of TGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers." Cells (2073-4409) 13, no. 24 (2024): 2087. https://doi.org/10.3390/cells13242087.

MLA (9th ed.) Citation

Manore, Sara, et al. "Co-Inhibition of TGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers." Cells (2073-4409), vol. 13, no. 24, 2024, p. 2087, https://doi.org/10.3390/cells13242087.